Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective

Clinical Microbiology and Infection

Volumn 21, Issue 10, 2015, Pages 881-885

  Muller, A E ^a   Theuretzbacher, U ^b   Mouton, J W ^c,d  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

^b Centre for Anti Infective Agents   (Austria)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dose optimization; Effectiveness; PK PD; Registration; Revived antibiotics

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG INDICATION; DRUG USE; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; ADVERSE DRUG REACTION; BACTERIAL INFECTIONS; DRUG APPROVAL; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG APPROVAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS;

EID: 84942122477     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.06.007     Document Type: Review

References (21)

1. Murni I.K., Duke T., Kinney S., Daley A.J., Soenarto Y. Reducing hospital-acquired infections and improving the rational use of antibiotics in a developing country: An effectiveness study. Arch Dis Child 2015, 100:454-459.
2. Kotwani A., Wattal C., Joshi P.C., Holloway K. Irrational use of antibiotics and role of the pharmacist: An insight from a qualitative study in new delhi, india. J Clin Pharm Ther 2012, 37:308-312.
3. Podolsky S.H. Antibiotics and the social history of the controlled clinical trial, 1950-1970. J Hist Med Allied Sci 2010, 65:327-367.
4. Theuretzbacher U. Product information for parenteral colistin varies substantially across Europe. J Antimicrob Chemother 2014, 69:1987-1992.
5. European Medicines Agency New EMA guidance on development of antibacterials to help in the fight against multidrug-resistant pathogens 2013, Press release, http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001944.jsp&mid=WC0b01ac058004d5c1. (accessed 15.05.15).
6. European Medicines Agency Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections 2011, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003417.pdf. (accessed 15.05.15).
7. European Medicines Agency Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections 2013, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003417.pdf. (accessed 15.05.15).
8. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for industry antibacterial drug products: Use of noninferiority trials to support approval 2010, FDA, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070951.pdf. (accessed 15.05.15).
9. Mouton J.W., Brown D.F., Apfalter P., Canton R., Giske C.G., Ivanova M., et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect. 2012, 18(3):E37-E45. Epub 2012/01/24.
10. Ambrose P.G., Bhavnani S.M., Rubino C.M., Louie A., Gumbo T., Forrest A., et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007, 44(1):79-86.
11. Sime F.B., Roberts M.S., Roberts J.A. Optimization of dosing regimens and dosing in special populations. Clin Microbiol Infect 2015, 21:886-893.
12. Grayson M.L., Crowe S.M., McCarthy J.S., Mills J., Mouton J.W., Norrby S.R., et al. Kucers' the use of antibiotics 2010, Hodder Arnold, London. 6th ed.
13. Muller A.E., Punt N., Mouton J.W. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 2013, 68:900-906.
14. Abdul-Aziz M.H., Lipman J., Mouton J.W., Hope W.W., Roberts J.A. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Resp Crit Care Med 2015, 36:136-153.
15. Nation R.L., Li J., Cars O., Couet W., Dudley M.N., Kaye K.S., et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015, 15(2):225-234. Epub 2014/12/03.
16. Huttner A., Verhaegh E.M., Harbarth S., Muller A.E., Theuretzbacher U., Mouton J.W. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015, Epub 2015/06/13.
17. Mouton J.W. Breakpoints: Current practice and future perspectives. Int J Antimicrob Agents 2002, 19:323-331.
18. Mouton J.W., Ambrose P.G., Kahlmeter G., Wikler M., Craig W.A. Applying pharmacodynamics for susceptibility breakpoint selection and susceptibility testing. Antimicrobial pharmacodynamics in theory and clinical practice 2007, 21-44. Informa Health Care, New York. C. Nightingale, P.G. Ambrose, G.L. Drusano, T. Mukisawa (Eds.).
19. European Commission AIDA-Preserving old antibiotics for the future: assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics 2011, Community Research and Development Information Service, http://cordis.europa.eu/project/rcn/101361_en.html. (accessed 15.05.15).
20. National Institutes of Health NIH funds four clinical trials to fight antimicrobial resistance 2010, NIH News.
21. Harbarth S., Theuretzbacher U., Hackett J. Antibiotic research and development: business as usual?. J Antimicrob Chemother. 2015, 70(6):1604-1607. consortium D-A, Epub 2015/02/13.